Name : Mr.

DIGVIJAY Order ID : 4130507

Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364919 Sample Receive Date : 14/Feb/2022 02:57PM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA Report Date : 14/Feb/2022 03:21PM

HAEMATOLOGY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Complete Blood Count

Hemoglobin 15.3 g/dL 13.0-17.0 Cyanide-free SLS-
Hemoglobin
RBC 5.05 mili/cu.mm 4.5 - 5.5 DC Impedence Method
HCT 44.8 % 40 - 50 RBC pulse height detection
MCV 88.7 fl 83 - 101 Calculated
MCH 30.3 pg 27 - 32 Calculated
MCHC 34.2 g/dL 31.5 - 34.5 Calculated
RDW-SD 40.7 fL 39 - 46 Calculated
RDW-CV 12.4 % 11.6 - 14.0 Calculated
Total Leucocyte Count 7.7 10^3/µI 4 - 10 Flowcytometery/Microscopic
Differential Leucocyte Count
Neutrophils 59.1 % 40-80 Flowcytometery/Microscopic
Lymphocytes 31.2 % 20-40 Flowcytometery/Microscopic
Monocytes 6.8 % 2-10 Flowcytometery/Microscopic
Eosinophils 2.6 % 1-6 Flowcytometery/Microscopic
Basophils 0.3 % 0-2 Flowcytometery/Microscopic
Absolute Leucocyte Count
Absolute Neutrophil Count 4.55 10^3/µI 2-7 Calculated
Absolute Lymphocyte Count 2.4 10^3/µI 1-3 Calculated
Absolute Monocyte Count 0.52 10^3/µI 0.2-1 Calculated
Absolute Eosinophil Count 0.2 10^3/µI 0.02-0.5 Calculated
Absolute Basophil Count 0.02 10^3/µI 0.02-0.1 Calculated
Platelet Count 247 10^3/µI 150-410 Electrical
Impedence/Microscopic
MPV 12.6 fl 6.5 - 12 Calculated
PDW 17 fL Calculated

Kindly correlate clinically

Results relate only to the sample, as received

Page 1 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:13PM

BIOCHEMISTRY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Blood Urea Nitrogen 8.20 mg/dL 8.9 - 20.6 Urease

Creatinine 0.90 mg/dL 0.72-1.25 Kinetic Alkaline Picrate

Kindly correlate clinically

Results relate only to the sample, as received

Page 2 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364917 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : FLUORIDE PLASMA Report Date : 14/Feb/2022 04:07PM

BIOCHEMISTRY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Glucose - Fasting 87.0 mg/dL 70-105 Hexokinase/G-6-PDH

Comment:
Fasting Plasma Glucose 2 hr plasma Glucose Diagnosis
(mg/dL) (mg/dL)
99 or below 139 or below Normal
100 to 125 140 to 199 Pre-Diabetes (IGT)
126 or above 200 or above Diabetes

Reference : American Diabetes Association

Comment :
Impaired glucose tolerance (IGT) fasting, means a person has an increased risk of developing type 2 diabetes but does not have it yet. A
level of 126 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes.
IGT (2 hrs Post meal ), means a person has an increased risk of developing type 2 diabetes but does not have it yet. A 2-hour glucose
level of 200 mg/dL or above, confirmed by repeating the test on another day, means a person has diabetes

Plasma Glucose Goals For people with Diabetes

Before meal 70-130 mg/dL
2 Hours after meal Less than 180 mg/dL
HbA1c Less than 7%

Kindly correlate clinically

Results relate only to the sample, as received

Page 3 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:13PM

BIOCHEMISTRY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Lipid Profile
Cholesterol 186 mg/dL Desirable <200, Enzymatic
Borderline High 200 -
239,
High >=240
Triglycerides 174 mg/dL Normal: < 150, Glycerol Phosphate
Borderline: 150 - 199, Oxidase
High:200 - 499,
Very High >=500
HDL Cholesterol 36 mg/dL 40 - 60 Accelerator Selective
Detergent
LDL Cholesterol 115 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
VLDL Cholesterol 35 mg/dL 10 - 30 Calculated
Cholesterol : HDL Cholesterol 5.2 Ratio Calculated
HDL/LDL Ratio 0.31 Ratio Calculated
LDL/HDL Ratio 3.20 Ratio Calculated
Non-HDL Cholesterol 150 mg/dL Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220

Kindly correlate clinically

Results relate only to the sample, as received

Page 4 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:13PM

BIOCHEMISTRY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Comment:

In all adults (>=20 years of age), a fasting lipoprotein profile should be obtained at least every 5 years. The measurement and monitoring
of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy. An elevated level of cholesterol
carried by circulating apolipoprotein B-containing lipoproteins (non–high-density lipoprotein cholesterol and low-density lipoprotein
cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most
clinical atherosclerotic cardiovascular disease (ASCVD) events.
Reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is
reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug
therapies.

Atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore,
both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-
reduction therapies.

Nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes
mellitus.

High triglycerides levels - obesity, physical inactivity, smoking, excess alcohol intake, high carbohydrate diet, type2 diabetes, chronic
renal failure, nephritic syndrome, certain drugs (e.g. corticosteroids, estrogens,retinoids, Beta blockers), and genetic disorders(e.g. familial
combined hyperlipidemia, familial hypertriglyceridemia,familial dysbetalipoproteinemia)

Kindly correlate clinically

Results relate only to the sample, as received

Page 5 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:13PM

BIOCHEMISTRY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Liver Function Test

Bilirubin-Total 0.69 mg/dL 0.2-1.2 Diazonium Salt
Bilirubin-Direct 0.24 mg/dL 0-0.5 Diazo
Bilirubin-Indirect 0.45 mg/dL 0 - 1.8 Calculated
Protein, Total 7.64 g/dL 6.0-8.3 Biuret
Albumin 4.42 g/dL 3.5-5.2 Bromocresol Green
Globulin 3.2 g/dl 1.8 - 3.6 Calculated
A/G Ratio 1.4 Ratio Calculated
Aspartate Transaminase (SGOT) 19 U/L 5-34 NADH w/o P-5’-P
Alanine Transaminase (SGPT) 19 U/L 5-55 NADH w/o P-5’-P
SGOT/SGPT 1.00 Ratio Calculated
Alkaline Phosphatase 94.00 U/L 40-150 Para-nitrophenyl
phosphate
Gamma Glutamyltransferase (GGT) 17 U/L 12-64 L-gamma-glutamyl-3-
Carboxy-4-Nitroanilide

Comment:
LFTS are based upon measurements of substances released from damaged hepatic cells into the blood that gives idea of the Existence, Extent and Type of Liver
damage.
- Acute Hepatocellular damage: ALT & AST levels are sensitive index of hepatocellular damage
- Obstruction to the biliary tract,Cholestasis and blockage of bile flow:
1) Serum Total Bilirubin concentration 2) Serum Alkaline Phosphatase (ALP) activity 3) Gamma Glutamyl Transpeptidase (GGTP) 4) 5`-Nucleotidase
- Chronic liver disease: Serum Albumin concentration
Bilirubin results from the enzymatic breakdown of heme. Jaundice is a yellowish discoloration of the skin and mucous membranes caused by hyperbilirubinemia.
Pre-hepatic or hemolytic jaundice - Abnormal red cells, antibodies,drugs and toxins,Hemoglobinopathies, Gilbert’s syndrome, Crigler-Najjar syndrome
Hepatic or Hepatocellular jaundice-Viral hepatitis,toxic hepatitis, intrahepatic cholestasis
Post-hepatic jaundice -Extrahepatic cholestasis, gallstones, tumors of the bile duct, carcinoma of pancreas
In viral hepatitis and other forms of liver disease associated with acute hepatic necrosis, serum AST and ALT concentrations are elevated even before the
clinical signs and symptoms of disease appear. ALT is the more liver-specific enzyme and elevations of ALT activity persist longer than AST activity. Peak
values of aminotransferase activity occur between the seventh and twelfth days. Activities then gradually decrease, reaching normal activities by the third
to fifth week. Peak activities bear no relationship to prognosis and may fall with worsening of the patient's condition.
Aminotransferase activities observed in cirrhosis vary with the status of the cirrhotic process and range from the upper reference limit to four to five
times higher, with an AST/ALT ratio greater than 1. The ratio's elevation can reflect the grade of fibrosis in these patients. Slight or moderate elevations
of both AST and ALT activities have been observed after administration of various medications and chronic hepatic injury such as (1) hemochromatosis, (2)
Wilson disease, (3) autoimmune hepatitis, (4) primary biliary cirrhosis, (5) sclerosing cholangitis, and (6) a1-antitrypsin deficiency. AST activity also is
increased in acute myocardial infarction, progressive muscular dystrophy and dermatomyositis, reaching concentrations up to eight times the upper reference
limit.Slight to moderate AST elevations are noted in hemolytic disease.

Kindly correlate clinically

Results relate only to the sample, as received

Page 6 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:13PM

BIOCHEMISTRY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method
GGT is a sensitive indicator of the presence of hepatobiliary disease, being elevated in most subjects with liver disease regardless of cause. Increased
concentrations of the enzyme are also found in serum of subjects receiving anticonvulsant drugs, such as phenytoin and phenobarbital.

Kindly correlate clinically

Results relate only to the sample, as received

Page 7 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:13PM

BIOCHEMISTRY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Urea 17.55 mg/dL 19.0 - 44.0 Calculated

Uric Acid 6.1 mg/dL 3.5-7.2 Uricase

Comment:
Long-term follow-up of asymptomatic hyperuricemic patients is undertaken because many are at risk for kidney disease that may develop as a result of hyperuricemia
and hyperuricuria; few of these patients ever develop the clinical syndrome of gout.. It is also used in the diagnosis and monitoring of pregnancy-induced hypertension
(pre- eclamptic toxemia). Concentrations in excess of 6.0 mg/dL at 32 weeks gestation have been noted to be associated with a high perinatal mortality rate.

Kindly correlate clinically

Results relate only to the sample, as received

Page 8 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:51PM

Immunology
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Thyroid Stimulating Hormone - Ultra 6.890 µIU/mL 0.35-4.94 CMIA

Sensitive

Comment:
Thyroid dysfunction is common in the general population and Laboratory tests are essential for the accurate diagnosis and cost-effective
monitoring of thyroid dysfunction. TSH is now firmly established as the first-line thyroid function test to assess thyroid status for most
clinical conditions. Interpretation of the results of thyroid function tests is facilitated by an understanding of thyroid hormone physiology,
especially the normal inverse relationship between free T4and TSH concentrations.Changes in thyroid status are normally associated with
concordant changes in T3,T4 and TSH concentrations (e.g. raised T4 and T3 with suppressed TSH in thyrotoxicosis; low T4 and T3
with elevated TSH in hypothyroidism). An abnormal TSH requires further investigation, including measurement of free T4. In most
clinical situations involving discordant FT4 and TSH results, the TSH test usually yields the most diagnostically reliable result, provided
that the patient is not receiving medications that directly inhibit TSH secretion, and there are no conditions affecting the pituitary-thyroid
axis.. Using TSH as a single criterion has been shown to accurately classify the thyroid state of a patient in over 95% of cases. Non-
thyroidal illness (NTI), pituitary disease and various drugs can all affect the axis and cause discrepancies between TSH levels, thyroid
hormone levels and the clinical state. Measurement of the TSH level is indicated for patients with symptoms suggestive of thyroid
dysfunction, reduced bone mineral density, dyslipidaemia, depression, or atrial fibrillation.
Total T4 measures the total amount of thyroxine circulating in the bloodstream. Indications:Used to make diagnosis of underactive or
overactive thyroid when TSH is abnormal • Used with TSH for monitoring patients with Graves’ disease • Newborn screening test for
hypothyroidism • Fairly accurate in patients with no protein abnormalities and not pregnant Free T4 measures the available, unbound
amount of thyroxine in the bloodstream.
Free T4 is critical for evaluating patients with hypothalamic-pituitary disease. It is also useful for evaluating the response to levothyroxine
in cases of poor compliance and in the first months of treating patients with chronic, severe hypothyroidism.
The total T3 test measures the total amount of triiodothyronine circulating in the bloodstream. Free T3 measures the free, unbound levels
of the hormone triiodothyronine available for use by the body.Total T3 measurements, however, should be performedIn patients
suspected of having T3 thyrotoxicosis and in patients taking drugs that inhibit the peripheral conversion of T4 to T3 (such as
dexamethasone, propranolol, propylthiouracil, amiodarone, and iodine-containing contrast media)
Maternal hypothyroidism causes adverse effects on fetal psychomotor development, highlighting the significance of evaluating thyroid
function during pregnancy.Tests should be performed pre-pregnancy or in the first trimester with TSH tests that can detect mild thyroid
failure. During pregnancy, the total levels of T3 and T4 are high because of increased TBG, and free T4 levels may slightly increase
during the first trimester but will subsequently decline in the second and third trimesters.
In addition to the pre-analytical factors, potential analytical factors that interfere with the thyroid function tests assays such as heterophilic
antibodies and autoantibodies, may lead to discordant thyroid function test results. The optimal use of thyroid function tests should be
patient-specific and depends on the patient’s specific thyroid disease, the stage of the disease and co-existing medical conditions. Results
should be interpreted in the appropriate clinical context of the individual patient with good communication between clinicians and the

Kindly correlate clinically

Results relate only to the sample, as received

Page 9 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364918 Sample Receive Date : 14/Feb/2022 03:52PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum Report Date : 14/Feb/2022 04:51PM

Immunology
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method
requesting test laboratory.

Kindly correlate clinically

Results relate only to the sample, as received

Page 10 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364920 Sample Receive Date : 14/Feb/2022 03:03PM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine Report Date : 14/Feb/2022 04:55PM

CLINICAL PATHOLOGY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method

Urine Routine & Microscopy

Colour PALE YELLOW Pale Yellow Manual
Appearance CLEAR Clear Manual
Specific gravity 1.015 1.005 - 1.030 pKa change
Ph 6.5 5.0 - 8.5 Double Indicator
Glucose Negative Negative GOD-POD
Protein Negative Negative Protein Error Principle
Ketones Negative Negative Nitroprusside
Blood Negative Negative Peroxidase
Bilirubin Negative Negative Diazonium
Urobilinogen Normal Normal Ehrlich
Leucocyte Esterase Negative Negative Pyrrole
Nitrite Negative Negative Sulphanilamide
Pus cells 1-2 /hpf 0-5 Microscopy
Red Blood Cells NIL /hpf 0-2 Microscopy
Epithelial cells 1-2 /hpf Few Microscopy
Casts NIL Nil Microscopy
Crystals NIL Nil Microscopy
Yeast NIL Nil Microscopy
Bacteria NIL Nil Microscopy

Comment:
Pre-test condition to be observed while submitting the sample-first void, mid stream urine, collected in a clean, dry, sterile container is
recommended for routine urine analysis, avoid contamination with any discharge from vaginal, urethra, perineum, as applicable, avoid
prolonged transit time & undue exposure to sunlight. During interpretation, points to be considered are Negative nitrite test does not
exclude the urinary tract infections. Trace proteinuria can be seen with many physiological conditions like prolonged recumbency,
exercise, high protein diet. False positive reactions for bile pigments, proteins, glucose and nitrites can be caused by peroxidase like
activity by disinfectants, therapeutic dyes, ascorbic acid and certain drugs.

Kindly correlate clinically

Results relate only to the sample, as received

Page 11 of 12
 Name : Mr.DIGVIJAY Order ID : 4130507
Age/Gender : 35/Male Registration Date : 14-Feb-22 01:05 PM
Patient ID : MGB70964 Collection Date : 14/Feb/2022 09:44AM
Barcode ID : A6364920 Sample Receive Date : 14/Feb/2022 03:03PM
Referred By : Dr. Report Status : Final Report
Sample Type : Urine Report Date : 14/Feb/2022 04:55PM

CLINICAL PATHOLOGY
GOOD HEALTH SILVER PACKAGE
Test Name Result Unit Bio. Ref. Range Method
*** End Of Report ***

Kindly correlate clinically

Results relate only to the sample, as received

Page 12 of 12